Janet Conway, MD, completed the first U.S. cases using Bonesupport's Cerament G for osteomyelitis.
Cement G received FDA authorization earlier in 2022, according to an Oct. 24 company news release. It addresses the site of infection with a single-stage surgical approach. A clinical study found Cerament G reduces the risk of bone infection to 4.3 to 5.5 percent compared to 13.3 percent with standard care.
Cerament G is the first FDA approved combination antibiotic-eluting bone graft. Dr. Conway is head of bone and joint infection at Sinai Hospital of Baltimore.